NVCT

Nuvectis Pharma Inc

Jun 23 • 04:00PM ET

17.55

+1.02 6.17 %

Healthcare • Biotechnology • USA • Small • NASD

Jun 22, 7:35 AMNuvectis Pharma signs ex-China license deal with Haisco for NXP100 and NXP200, worth up to $40M upfront and $1.421B in milestones

Peers: ALXO FHTX BCYC CGEN FATE CDXS IKT NBP NERV AKTX

| Held by: IWM VTI VXF IWO VTWO IWC GSSC VTWG RSSL VTHR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.27	Insider Own	42.13%	Shs Outstand	26.53M	Perf Week	57.40%
Market Cap	465.53M	Forward P/E	-	EPS next Y	-1.06	Insider Trans	0.00%	Shs Float	15.35M	Perf Month	60.42%
Enterprise Value	440.40M	PEG	-	EPS next Q	-0.26	Inst Own	17.15%	Short Float	10.30%	Perf Quarter	112.47%
Income	-29.59M	P/S	-	EPS this Y	21.52%	Inst Trans	2.03%	Short Ratio	17.11	Perf Half Y	119.92%
Sales	0.00M	P/B	32.74	EPS next Y	-2.70%	ROA	-106.54%	Short Interest	1.58M	Perf YTD	132.45%
Book/sh	0.54	P/C	18.52	EPS next 5Y	-1.86%	ROE	-168.24%	52W High	16.64 5.47%	Perf Year	120.48%
Cash/sh	0.95	P/FCF	-	EPS past 3/5Y	4.25% -340.28%	ROIC	-208.08%	52W Low	5.55 216.22%	Perf 3Y	3.54%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	13.97% 7.73%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-16.88%	Oper. Margin	-	ATR (14)	1.04	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.27	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	87.13	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.27	EPS Q/Q	3.37%	SMA20	57.89%	Beta	-0.23	Target Price	29.20
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	71.26%	Rel Volume	3.04	Prev Close	16.53
Employees	13	LT Debt/Eq	0.00	Earnings	May 05 BMO	SMA200	116.75%	Avg Volume	92.40K	Price	17.55
IPO	Feb 04, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	17.20% -	Trades		Volume	280,732	Change	6.17%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-25	Initiated	Maxim Group	Buy	$17
Mar-17-25	Initiated	Laidlaw	Buy	$19
Jul-13-22	Initiated	Ladenburg Thalmann	Buy	$21

Jun-22-26 08:53AM	Nuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT) (InvestorsHub) +19.61%
07:30AM	Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds (GlobeNewswire)
May-14-26 07:30AM	Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-05-26 07:30AM	Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights (GlobeNewswire) +9.22%
Mar-31-26 08:00AM	Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting (GlobeNewswire)
07:30AM	Loading…
Feb-11-26 07:30AM	Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights (GlobeNewswire)
Dec-17-25 07:00AM	Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC (GlobeNewswire)
Nov-25-25 08:00AM	Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC (GlobeNewswire)
Nov-04-25 08:15AM	CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) -7.55%
07:30AM	Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Oct-27-25 08:00AM	Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +5.65%
Oct-16-25 08:00AM	Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-25-25 08:00AM	Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors (GlobeNewswire)
Sep-04-25 07:30AM	Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-11-25 04:30PM	Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 (GlobeNewswire) +11.26%
07:30AM	Loading…
Aug-05-25 07:30AM	Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) -5.35%
Aug-04-25 07:41AM	Nuvectis Pharma cuts NXP800 in ovarian cancer after early failure (Clinical Trials Arena) +7.21%
Jul-31-25 07:45AM	Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study (GlobeNewswire) -7.81%
Jul-08-25 08:00AM	Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies (GlobeNewswire)
May-16-25 04:35PM	Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) +6.36% +10.94%
May-09-25 09:55AM	Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect? (Zacks)
May-06-25 08:00AM	Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Apr-30-25 05:28AM	Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025 (Insider Monkey)
Apr-29-25 04:25PM	Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting (GlobeNewswire)
Mar-26-25 08:00AM	Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting (GlobeNewswire)
Mar-14-25 08:00AM	Nuvectis Pharma to Participate in the 37th Annual Roth Conference (GlobeNewswire) +5.99%
Mar-05-25 08:44AM	Market News Alert: Nuvectis Pharmas NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation (Business Wire)
Mar-04-25 08:00AM	Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC (GlobeNewswire)
Feb-27-25 10:43AM	Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets (Business Wire)
Feb-25-25 08:00AM	Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights (GlobeNewswire) -5.84%
08:30AM	Loading…
Feb-07-25 08:30AM	Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option (GlobeNewswire) -7.32%
Feb-05-25 09:01AM	Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock (GlobeNewswire)
Feb-04-25 04:05PM	Nuvectis Pharma Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Dec-10-24 08:00AM	Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators and Investors Symposium (GlobeNewswire)
08:00AM	Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium (GlobeNewswire)
Nov-25-24 09:55AM	Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Nov-15-24 07:45AM	Nuvectis Pharma reports data from Phase 1b study of NXP800 (TipRanks) -13.61%
Nov-14-24 02:23PM	Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug (Benzinga) -46.30%
07:00AM	Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer (GlobeNewswire)
Nov-13-24 08:50AM	Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Nov-07-24 09:55AM	Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know (Zacks)
Nov-05-24 07:00AM	Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +17.75%
Oct-28-24 08:21AM	PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update (Business Wire) -10.50%
Oct-23-24 08:00AM	Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +5.33%
Oct-07-24 08:00AM	Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-16-24 07:15AM	PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch (Business Wire)
Sep-05-24 08:00AM	Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.81%
Aug-30-24 06:52AM	Nuvectis NXP800 gains FDA ODD for cancer treatment (Pharmaceutical Technology)
Aug-29-24 08:00AM	Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers (GlobeNewswire)
Aug-06-24 08:28AM	Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -5.83%
May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace) +5.96%
May-24-24 09:55AM	Wall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High? (Zacks) -7.04%
May-16-24 08:30AM	Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
May-07-24 09:06PM	Nuvectis Pharma Inc Reports Q1 2024 Financial Outcomes (GuruFocus.com) -10.57%
01:53PM	NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Apr-08-24 08:30AM	Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines (GlobeNewswire)
Apr-02-24 04:30PM	5 Healthcare Stocks to Buy for 2024 (InvestorPlace)
Mar-19-24 08:00AM	Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting (GlobeNewswire) -16.08%
Mar-15-24 08:00AM	Nuvectis Pharma to Present at the 36th Annual Roth Conference (GlobeNewswire) +20.22%
Mar-14-24 09:00AM	Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer (GlobeNewswire) -5.08%
Mar-05-24 11:52PM	NVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023 (InvestorPlace)
08:31AM	Nuvectis Pharma Inc (NVCT) Reports Increased Net Loss in FY 2023 Despite Clinical Progress (GuruFocus.com)
08:00AM	Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Feb-09-24 08:32AM	Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Nuvectis Pharma Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Jan-03-24 08:00AM	Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 08:00AM	Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma (GlobeNewswire)
Nov-08-23 08:00AM	Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) -7.83%
Oct-24-23 08:00AM	Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer (GlobeNewswire)
Oct-16-23 09:35AM	Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT) (Zacks) +15.87%
Sep-25-23 07:30PM	Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation (GlobeNewswire)
Sep-21-23 08:00AM	Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900 (GlobeNewswire)
Sep-12-23 08:00AM	Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial (GlobeNewswire)
Sep-06-23 08:00AM	Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900 (GlobeNewswire)
Sep-01-23 08:00AM	Nuvectis Pharma Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-17-23 08:00AM	Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma (GlobeNewswire)
Aug-11-23 07:01AM	Daily Vickers Top Insider Picks for 08/11/2023 (Argus Research)
Aug-10-23 06:24AM	Daily Vickers Top Insider Picks for 08/10/2023 (Argus Research)
Aug-09-23 08:00AM	Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
06:26AM	Daily Vickers Top Insider Picks for 08/09/2023 (Argus Research)
Aug-08-23 06:28AM	Daily Vickers Top Insider Picks for 08/08/2023 (Argus Research)
Aug-07-23 06:35AM	Daily Vickers Top Insider Picks for 08/07/2023 (Argus Research)
Aug-04-23 07:14AM	Daily Vickers Top Insider Picks for 08/04/2023 (Argus Research)
Aug-03-23 07:15AM	Daily Vickers Top Insider Picks for 08/03/2023 (Argus Research)
Aug-02-23 07:52AM	Daily Vickers Top Insider Picks for 08/02/2023 (Argus Research) +7.41%
Aug-01-23 06:51AM	Daily Vickers Top Insider Picks for 08/01/2023 (Argus Research)
06:51AM	Daily Vickers Top Buyers & Sellers for 08/01/2023 (Argus Research)
Jul-31-23 06:44AM	Daily Vickers Top Insider Picks for 07/31/2023 (Argus Research)
Jul-28-23 07:58AM	Daily Vickers Top Insider Picks for 07/28/2023 (Argus Research)
07:58AM	Daily Vickers Top Buyers & Sellers for 07/28/2023 (Argus Research)
Jul-27-23 07:10AM	Daily Vickers Top Insider Picks for 07/27/2023 (Argus Research)
Jul-26-23 01:12PM	Daily Vickers Top Insider Picks for 07/26/2023 (Argus Research)
Jul-25-23 07:16AM	Daily Vickers Top Insider Picks for 07/25/2023 (Argus Research)
07:16AM	Daily Vickers Top Buyers & Sellers for 07/25/2023 (Argus Research)
Jul-24-23 07:12AM	Daily Vickers Top Insider Picks for 07/24/2023 (Argus Research)
Jul-21-23 07:23AM	Daily Vickers Top Insider Picks for 07/21/2023 (Argus Research) +5.18%
07:23AM	Daily Vickers Top Buyers & Sellers for 07/21/2023 (Argus Research)
Jul-20-23 06:55AM	Daily Vickers Top Insider Picks for 07/20/2023 (Argus Research)
06:55AM	Daily Vickers Top Buyers & Sellers for 07/20/2023 (Argus Research)

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its product pipeline includes NXP800 and NXP900. The company was founded by Ronald E. Bentsur, Enrique Poradosu, and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.

Co-FounderMr. Ron Bentsur M.B.A.

Co-FounderDr. Enrique Poradosu Ph.D.

Co-FounderMr. Shay Shemesh

Vice President of FinanceMr. Michael Carson CPA

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BENTSUR RON	Chairman & CEO	Nov 05 '25	Buy	5.72	5,000	28,600	3,525,924	Nov 06 08:01 AM
Sanchez Juan	Director	Nov 05 '25	Buy	5.79	13,000	75,270	78,150	Nov 06 08:00 AM
Kaplan Matthew L.	Director	Nov 05 '25	Buy	5.84	11,000	64,240	124,760	Nov 06 08:00 AM
Mosseri Marlio Charles	10% Owner	Oct 27 '25	Buy	6.28	72,836	457,410	3,136,576	Oct 29 08:00 AM
Mosseri Marlio Charles	10% Owner	Oct 23 '25	Buy	6.06	46,900	284,214	3,028,706	Oct 29 08:00 AM
Mosseri Marlio Charles	10% Owner	Oct 24 '25	Buy	6.15	35,034	215,459	3,063,740	Oct 29 08:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVCT

Nuvectis Pharma Inc

Upgrade your Finviz experience